Tris Pharma Bags US FDA Nod For Clonidine Hydrochloride

The US Food and Drug Administration (FDA) has approved Onyda XR (clonidine hydrochloride), a once-daily extended-release oral suspension with nighttime dosing, for the treatment of attention deficit hyperactivity disorder (ADHD) in pediatric patients six years of age and older. Tris Pharma, Inc. (Tris) is a commercial-stage biopharmaceutical company focused on attention deficit hyperactivity disorder (ADHD), pain, addiction, and neurological disorders.

Onyda XR is Tris' first non-stimulant ADHD drug, the only liquid non-stimulant ADHD medication approved in the United States, and the only non-stimulant ADHD medication approved for nocturnal use. Non-stimulant ADHD therapies are an essential choice for individuals who do not respond well to stimulant medication or who experience bad side effects from it, and they are becoming more popular as a viable alternative to stimulant treatments. 

“People with ADHD require a range of therapeutic options that are designed for their individual needs, because not every medication or type of therapy works for every patient,” said Ann Childress, M.D. “The approval of Onyda XR, the only liquid non-stimulant ADHD medication, with nighttime dosing that shifts the release profile, is a convenient option for patients needing better ADHD control.”

The pharmaceutical company used the flexibility of its unique LiquiXR technology to create Onyda XR, a liquid non-stimulant medicine with a smooth, extended-release profile that doctors can employ to treat ADHD patients alone or in combination with stimulant therapy. This product adds to Tris' extensive and growing range of top ADHD medicines that improve patient care for those with the disorder.